AstraZeneca loses appeal at Court of Justice
Pharma companies in Europe should reconsider their antitrust risk following a ruling by the Court of Justice this morning
In a relatively straightforward decision, the Court dismissed AstraZeneca's appeal of a General Court ruling that had in turn largely upheld a finding by the European Commission in 2005.
That finding imposed a fine of €60 million on AstraZeneca...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.